Clinical trial NCT00768599: A Study of Econazole Foam 1% in Athlete's Foot
Official title: A Multi-Center Randomized, Evaluator-Blinded, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1%, Econazole Nitrate 1% Cream, and Foam Vehicle in Subjects With Tinea Pedis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Tinea Pedis
Athlete's Foot
Keywords: Econazole
Foam
Quinnova
Lead sponsor: AmDerma
Sponsor class: INDUSTRY
First posted: 2008-10-08
Enrollment: 135
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a 6-week clinical study (4 weeks of treatment, once per day, plus a 2-week follow-up period) of a topical foam to treat athlete's foot. The active ingredient in the foam -- econazole nitrate 1% -- is the same active pharmaceutical ingredient in a cream that your doctor can currently prescribe to treat athlete's foot. This study will help to understand if the foam works the same as the cream to treat athlete's foot.

Detailed description: Treating athlete's foot with a cream can leave a greasy, wet feeling on the foot that is uncomfortable to the user and messy on clothing and foot wear. A foam formulation that spreads easily and rubs-in easily that is as effective as the (reference) cream formulation in treating athlete's foot would be a benefit to the user. This study is designed to substantiate a clinical bridge between econazole nitrate foam 1% and econazole nitrate cream 1% based on clinical outcome, safety, and pharmacokinetic data. The study is (foam) vehicle-controlled and is randomized 1 to 1 to 1 (foam:cream:vehicle).

Eligibility criteria: Inclusion Criteria:

* Be at least 18 years or age and of either sex.
* Has a clinical diagnosis of tinea pedis with at least i) moderate scaling(interdigital and/or moccasin) and ii) mild erythema (interdigital only).
* Be willing to give informed consent.
* Be willing and able to give informed consent.
* Has microscopic evidence (positive KOH) of the presence of fungi. Evaluable subjects must have a positive KOH and a fungal culture positive for a dermatophyte at Baseline. Subjects with a positive KOH may be entered into the study pending the results of the fungal culture.
* Be in good health and free of any disease or physical condition which might, in the investigator's opinion, expose the subject to an unacceptable risk by study participation.
* Women of childbearing potential must have a negative urine pregnancy test and agree to use an effective, non-prohibited form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives for at least two months, implant, injection, IUD, patch, NuvaRing, condom and spermicidal or diaphragm and spermicidal).

Exclusion Criteria:

* Is nursing or planning a pregnancy during the study.
* Has used topical antifungal or corticosteroid therapy or systemic antibacterial therapy within 30 days prior to the start of the study.
* Has received systemic antifungal therapy within 12 weeks prior to the start of the study medication.
* Has a history of diabetes mellitus or is immunocompromised (due to disease, e.g., HIV, or medications).
* Has concurrent tinea infection (in the opinion of the investigator). However, concurrent onychomycosis is allowed.
* Has any other skin disease which might interfere with the evaluation of tinea pedis.
* Is currently enrolled in an investigational drug or device study.
* Has received an investigational drug or treatment with an investigational device within 30 days prior to entering this study
* Is unreliable, including subjects with a history of drug or alcohol abuse.
* Has known hypersensitivity to any of the components of the study medications.

Primary outcomes:
measure: Complete Cure Rate: Interdigital Disease
timeFrame: Day 43
measure: Complete Cure Rate: Moccasin Disease
timeFrame: 43 Days
Secondary outcomes:
measure: Effective Treatment: Interdigital Disease
timeFrame: 43
measure: Effective Treatment: Mocassin Disease
timeFrame: 43
measure: Mycological Cure: Interdigital Disease
timeFrame: 43
measure: Mycological Cure: Mocassin Disease
timeFrame: 43
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Stacy Smith, MD
state: California
city: Clinton Township
country: United States
facility: Daniel Stewart, DO
state: Michigan
city: Fridley
country: United States
facility: Steven Kempers, MD
state: Minnesota
city: Nashville
country: United States
facility: Michael Gold, MD
state: Tennessee
city: Austin
country: United States
facility: Michael Jarratt, MD
state: Texas
city: Salt Lake City
country: United States
facility: Leonard Swinyer, MD
state: Utah
Study officials:
References: